Felix Machleid
Papers
1
Total Citations
6
H-Index
1
About
Felix Machleid is a health economist and outcomes researcher whose work focuses on the cost-effectiveness of surgical innovations, particularly in urological oncology. His most cited study, a 2022 cost-utility analysis comparing robotic-assisted radical cystectomy (RARC) to open radical cystectomy (ORC) for bladder cancer in the UK, provides critical evidence for healthcare decision-making. By modeling long-term costs and quality-adjusted life years (QALYs), Machleid demonstrates how advanced surgical technologies can be evaluated for value in resource-constrained systems. This work, cited six times, addresses a key clinical question: whether the higher upfront costs of robotic surgery are justified by reduced complications and improved recovery. Beyond this flagship paper, his research contributes to the growing field of health technology assessment (HTA), bridging the gap between surgical practice and economic sustainability. Machleid’s analyses are essential for policymakers and clinicians navigating the adoption of expensive innovations, ensuring that patient outcomes and healthcare budgets are balanced. His work exemplifies how rigorous economic modeling can guide evidence-based adoption of cutting-edge treatments in oncology.
Research Focus
Key Achievements
Top Papers
- 1